Beta-arrestin-dependent formation of beta2 adrenergic receptor-Src protein kinase complexes. Luttrell LM, Ferguson SS, Daaka Y, Miller WE, Maudsley S, Della Rocca GJ, et al. Nuclear ARRB1 induces pseudohypoxia and cellular metabolism reprogramming in prostate cancer. Zecchini V, Madhu B, Russell R, Pertega-Gomes N, Warren A, Gaude E, et al. Beta-arrestin links endothelin A receptor to beta-catenin signaling to induce ovarian cancer cell invasion and metastasis. Rosano L, Cianfrocca R, Masi S, Spinella F, Di Castro V, Biroccio A, et al.
Arrestin2 modulates androgen receptor activation. Purayil HT, Zhang Y, Dey A, Gersey Z, Espana-Serrano L, Daaka Y. Functional desensitization of the isolated beta-adrenergic receptor by the beta-adrenergic receptor kinase: potential role of an analog of the retinal protein arrestin (48-kDa protein).
2004 25:413–22.īenovic JL, Kuhn H, Weyand I, Codina J, Caron MG, Lefkowitz RJ. Historical review: a brief history and personal retrospective of seven-transmembrane receptors. The androgen receptor can promote beta-catenin nuclear translocation independently of adenomatous polyposis coli. Mulholland DJ, Cheng H, Reid K, Rennie PS, Nelson CC. Inhibition of androgen receptor and beta-catenin activity in prostate cancer. Lee E, Madar A, David G, Garabedian MJ, Dasgupta R, Logan SK. Glucocorticoid receptor confers resistance to antiandrogens by bypassing androgen receptor blockade. 2017 355:84–88.Īrora VK, Schenkein E, Murali R, Subudhi SK, Wongvipat J, Balbas MD, et al. SOX2 promotes lineage plasticity and antiandrogen resistance in TP53- and RB1-deficient prostate cancer. Mu P, Zhang Z, Benelli M, Karthaus WR, Hoover E, Chen CC, et al. Rb1 and Trp53 cooperate to suppress prostate cancer lineage plasticity, metastasis, and antiandrogen resistance. Ku SY, Rosario S, Wang Y, Mu P, Seshadri M, Goodrich ZW, et al. The role of lineage plasticity in prostate cancer therapy resistance. 2007 28:778–808.īeltran H, Hruszkewycz A, Scher HI, Hildesheim J, Isaacs J, Yu EY, et al. Androgen receptor (AR) coregulators: a diversity of functions converging on and regulating the AR transcriptional complex. Testosterone and dihydrotestosterone tissue levels in recurrent prostate cancer. Titus MA, Schell MJ, Lih FB, Tomer KB, Mohler JL. Alternatively spliced androgen receptor variants. Drug insight: role of the androgen receptor in the development and progression of prostate cancer. Emerging mechanisms of resistance to androgen receptor inhibitors in prostate cancer. Emerging mechanisms of enzalutamide resistance in prostate cancer. 2020 70:7–30.Ĭlaessens F, Helsen C, Prekovic S, Van den Broeck T, Spans L, Van Poppel H, et al. The targeting of βArr1-regulated AR transcriptional function may be used in the development of new drugs to treat lethal CRPC. Functionally, we demonstrate that depletion of βArr1 attenuates PC cell and tumor growth and metastasis, and rescued expression of nuclear, but not cytosolic, βArr1 restores the PC colony growth and invasion of Matrigel in vitro and tumor growth and metastasis in mice. The βArr1 partitions to both nucleus and cytosol and mechanistic studies showed that nuclear, and not cytosolic, βArr1 formed a complex with AR and AR-coregulator βCatenin and that the heterotrimeric protein complex was recruited to androgen-response elements of AR-regulated genes. Further, βArr1 expression correlated with enhanced AR transcriptional function in these datasets. Unbiased gene expression analysis of public datasets revealed increased levels of ARRB1 (the gene encoding βArr1) in CRPC when compared to normal tissue. In this study, we identified ubiquitous βArrestin 1 (βArr1) as a regulator of AR function in CRPC. Hence, identification of factors involved in the regulation of AR expression and function is a necessary first-step to improve disease outcome. Progression of prostate cancer (PC) to terminal castration-resistant PC (CRPC) involves a diverse set of intermediates, and androgen receptor (AR) is the key mediator of PC initiation and progression to CRPC.
0 kommentar(er)
